TP53 and neoplasm: Compared with singularly targeting SR-BI, this multi-receptor-targeted approach increased drug accumulation in cancer cells in vitro and tumor xenografts in vivo, and was shown to enhance the dichlororacetate/p53-induced suppression of tumor growth in a model of lung adenocarcinoma (Zhang et al., 2010, 2016).